HomeCompareSLRN vs MCD

SLRN vs MCD: Dividend Comparison 2026

SLRN yields 88.11% · MCD yields 2.35%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SLRN wins by $2.29M in total portfolio value
10 years
SLRN
SLRN
● Live price
88.11%
Share price
$2.27
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.37M
Annual income
$731,873.50
Full SLRN calculator →
MCD
McDonald's Corporation
● Live price
2.35%
Share price
$308.53
Annual div
$7.26
5Y div CAGR
42.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$78.5K
Annual income
$26,227.70
Full MCD calculator →

Portfolio growth — SLRN vs MCD

📍 SLRN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSLRNMCD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SLRN + MCD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SLRN pays
MCD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SLRN
Annual income on $10K today (after 15% tax)
$7,488.99/yr
After 10yr DRIP, annual income (after tax)
$622,092.48/yr
MCD
Annual income on $10K today (after 15% tax)
$200.01/yr
After 10yr DRIP, annual income (after tax)
$22,293.55/yr
At 15% tax rate, SLRN beats the other by $599,798.93/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SLRN + MCD for your $10,000?

SLRN: 50%MCD: 50%
100% MCD50/50100% SLRN
Portfolio after 10yr
$1.22M
Annual income
$379,050.60/yr
Blended yield
31.01%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MCD right now

SLRN
Analyst Ratings
3
Buy
3
Hold
Consensus: Buy
Price Target
$10.50
+362.6% upside vs current
Range: $6.00 — $15.00
Altman Z
1.6
Piotroski
2/9
MCD
Analyst Ratings
37
Buy
23
Hold
1
Sell
Consensus: Buy
Price Target
$351.76
+14.0% upside vs current
Range: $320.00 — $385.00
Altman Z
4.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SLRN buys
0
MCD buys
0
No recent congressional trades found for SLRN or MCD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSLRNMCD
Forward yield88.11%2.35%
Annual dividend / share$2.00$7.26
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%42.3%
Portfolio after 10y$2.37M$78.5K
Annual income after 10y$731,873.50$26,227.70
Total dividends collected$2.08M$58.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyBuy
Analyst price target$10.50$351.76

Year-by-year: SLRN vs MCD ($10,000, DRIP)

YearSLRN PortfolioSLRN Income/yrMCD PortfolioMCD Income/yrGap
1← crossover$19,511$8,810.57$10,815$334.85+$8.7KSLRN
2$36,942$16,065.36$11,826$491.71+$25.1KSLRN
3$67,956$28,428.44$13,123$730.06+$54.8KSLRN
4$121,587$48,874.33$14,853$1,100.07+$106.7KSLRN
5$211,824$81,725.42$17,257$1,690.61+$194.6KSLRN
6$359,715$133,063.84$20,752$2,667.01+$339.0KSLRN
7$596,079$211,183.71$26,103$4,354.83+$570.0KSLRN
8$964,860$327,055.60$34,794$7,437.78+$930.1KSLRN
9$1,527,165$494,764.27$49,926$13,461.60+$1.48MSLRN
10$2,365,940$731,873.50$78,550$26,227.70+$2.29MSLRN

SLRN vs MCD: Complete Analysis 2026

SLRNStock

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.

Full SLRN Calculator →

MCDConsumer Discretionary

McDonald's Corporation operates and franchises McDonald's restaurants in the United States and internationally. Its restaurants offer hamburgers and cheeseburgers, chicken sandwiches and nuggets, wraps, fries, salads, oatmeal, shakes, desserts, sundaes, soft serve cones, bakery items, soft drinks, coffee, and beverages and other beverages, as well as breakfast menu, including biscuit and bagel sandwiches, breakfast burritos, hotcakes, and other sandwiches. As of December 31, 2021, the company operated 40,031 restaurants. McDonald's Corporation was founded in 1940 and is headquartered in Chicago, Illinois.

Full MCD Calculator →
📬

Get this SLRN vs MCD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SLRN vs SCHDSLRN vs JEPISLRN vs OSLRN vs KOSLRN vs MAINSLRN vs YUMSLRN vs QSRSLRN vs SBUX

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.